Sittner & Nelson’s Myriad Genetics MYGN Stock Holding History

Sittner & Nelson’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-150	Closed	-$3.67K	–	448
2024 Q2	$3.67K	Hold	150	–	–	﹤0.01%	401
2024 Q1	$3.2K	Hold	150	–	–	﹤0.01%	415
2023 Q4	$2.87K	Hold	150	–	–	﹤0.01%	412
2023 Q3	$2.41K	Hold	150	–	–	﹤0.01%	417
2023 Q2	$3.48K	Hold	150	–	–	﹤0.01%	426
2023 Q1	$3.48K	Hold	150	–	–	﹤0.01%	436
2022 Q4	$2.18K	Hold	150	–	–	﹤0.01%	424
2022 Q3	$3K	Hold	150	–	–	﹤0.01%	406
2022 Q2	$3K	Hold	150	–	–	﹤0.01%	434
2022 Q1	$4K	Hold	150	–	–	﹤0.01%	395
2021 Q4	$4K	Hold	150	–	–	﹤0.01%	391
2021 Q3	$5K	Hold	150	–	–	﹤0.01%	357
2021 Q2	$5K	Hold	150	–	–	﹤0.01%	336
2021 Q1	$5K	Hold	150	–	–	﹤0.01%	335
2020 Q4	$3K	Buy	+150	New	+$2.42K	﹤0.01%	365

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sittner & Nelson's MYGN Position: Q3 2024 in Review

Sittner & Nelson sold out of Myriad Genetics (MYGN) in Q3 2024, closing a stake of 150 shares — an estimated $3.67K sold.

Sittner & Nelson first reported a position in MYGN in Q4 2020 and held it in 15 quarters. The position peaked at $5K in Q3 2021. 246 funds tracked by Wall St. Rank hold MYGN as of Q3 2024.

Sittner & Nelson reported no remaining Myriad Genetics position as of Q3 2024 after selling out during the quarter.
Sittner & Nelson sold 150 Myriad Genetics shares in Q3 2024, an estimated $3.67K.
Sittner & Nelson first reported a position in Myriad Genetics in Q4 2020 and held it in 15 quarters.
Sittner & Nelson's Myriad Genetics position peaked at $5K in Q3 2021.
246 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2024.

Based on Sittner & Nelson's 13F filing for Q3 2024, filed 31 Oct 2024.